Arch Biopartners AI Stock Analysis
Want to see TSE:ARCH full AI Analyst Report?
Arch Biopartners (ARCH) AI Stock Analysis
Arch Biopartners
(TSXV:ARCH)
The overall score is severely constrained by the company's dire financial health, marked by zero revenue, negative equity, and a near-exhausted asset base. While technical indicators show some price stability and the cash burn rate is improving, these factors are insufficient to offset the fundamental risk of insolvency and the lack of any meaningful valuation support.
Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 64.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 43.51K
- Price to Earnings (P/E)
- -21.9
- Beta (1Y)
- 1.19
- Revenue Growth
- ―
- EPS Growth
- -15.53%
- Country
- Canada
- Employees
- 6
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Arch Biopartners Business Overview & Revenue Model
Company Description
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address...
Arch Biopartners Financial Statement Overview
Summary
The company is pre-revenue and technically insolvent with negative equity and minimal assets. While the rate of cash burn and net losses have narrowed, the complete lack of revenue and precarious balance sheet represent a critical financial risk, justifying the lowest possible score.
Income Statement
8Very NegativeBalance Sheet
1Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 2.12M | 1.98M | 964.68K | 3.89M |
| Gross Profit | 0 | 0 | -1.66M | -129.00K | -503.00K | -150.00K |
| EBITDA | -2.58M | -1.29M | -75.40K | -335.99K | -101.90K | -76.62K |
| Net Income | -2.83M | -1.55M | -3.92M | -3.33M | -1.41M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 57.22K | 104.53K | 935.62K | 1.17M | 621.64K | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 2,914 | 2,102 | 2,970 | 831.27K | 506.35K | 448.24K |
| Total Debt | 2.73M | 2.84M | 2.77M | 5.02M | 4.41M | 5.16M |
| Total Liabilities | 4.04M | 3.99M | 5.28M | 6.68M | 5.09M | 6.55M |
| Stockholders Equity | -3.99M | -3.88M | -4.35M | -5.51M | -4.47M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -1.72M | -1.58M | -2.33M | -234.08K | -1.08M | -2.98M |
| Operating Cash Flow | -1.72M | -1.58M | -2.33M | -234.07K | -1.08M | -2.98M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 1.55M | 1.58M | 1.50M | 559.00K | -421.37K | 2.78M |
Arch Biopartners Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.87, and above the 200-day MA of 0.76, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.98 is Neutral, neither overbought nor oversold. The STOCH value of 75.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ARCH.
Arch Biopartners Peers Comparison
Overall Rating
TSE:MSCL44Neutral
TSE:ARCH42Neutral
TSE:BCT42Neutral
TSE:MDNA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | CAD 194.98M | -3.05 | -77.81% | ― | ― | -32.01% | |
| 42Neutral | CAD 64.54M | -21.88 | 74.79% | ― | ― | -15.53% | |
| 42Neutral | CAD 41.30M | -0.35 | -170.70% | ― | ― | 87.90% | |
| 40Underperform | CAD 28.33M | -1.66 | -360.29% | ― | ― | -21.17% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ARCH | Arch Biopartners | 0.95 | -0.10 | -9.52% | |
| TSE:MSCL | Satellos Bioscience Inc. | 9.19 | 0.31 | 3.49% | |
| TSE:MDNA | Medicenna Therapeutics | 0.36 | -1.07 | -74.65% | |
| TSE:BCT | BriaCell Therapeutics | 4.73 | -5.37 | -53.17% | |
| TSE:METX | ME Therapeutics Holdings, Inc. | 1.05 | -2.95 | -73.75% | |
| TSE:ONCO | Onco-Innovations Ltd. | 1.47 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
